

INTERMOUNTAIN PRECISION GENOMICS CORE LAB PASSES CAP INSPECTION

CAP classification is a scientifically rigorous checklist of requirements

SALT LAKE CITY, UTAH, USA, January 8, 2016 /EINPresswire.com/ -- Intermountain Precision Genomics announced their core laboratory facility has received accreditation from The College of American Pathologists (CAP). The CAP classification is a scientifically rigorous checklist of requirements that indicate laboratories worldwide can demonstrate excellence in laboratory practices and inspire confidence in patient care.

The laboratory accreditation process by the College of American Pathologists inspects laboratories with a peer-based inspector model by the most respected pathology organization. According to laboratory manager David Loughmiller, the laboratory inspector was from a genomics lab at Stanford University and is heavily involved in writing the regulations relative to next-generation sequencing. "He was extremely qualified in being able to review our processes," Loughmiller said.

Preparation for the inspection required a comprehensive amount of validation to ensure the quality and performance of the methods used are well-suited to provide accurate information for ordering physicians and their patients. "The last three months have been a period of intense preparation," Loughmiller said. "Although, to pass the CAP inspection, the process started more than 12 months ago, including hiring the best and the brightest on this team."

Dr. Pravin Mishra, Clinical Laboratory Director for Intermountain Precision Genomics, spoke highly of the scientific background and experience at the lab. He said, "This successful CAP inspection allows us to solidify what we are offering for cancer patients, look to the future, start developing other assays for liquid biopsy, and perhaps double our gene panel for other diseases."

Intermountain Precision Genomics is a service of Intermountain Healthcare which offers genetic sequencing of solid tumors. This in-depth sequencing identifies individual mutations within a person's cancer cells to identify specific DNA targets for personalized drugs. For more information about Intermountain Precision Genomics please visit: precisioncancer.org, join the dialog on Facebook (Intermountain Precision Genomics) or follow @precisioncancer on Twitter.

Daron Cowley
Intermountain Healthcare

801-442-2834

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/305265812>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.